Skip to content

S. 652 · 119th Congress (2025–2027)

Protecting Patients from Deceptive Drug Ads Act

This bill establishes civil penalties for false or misleading communications about prescription drugs by certain entities on social media. It also requires additional disclosures and reporting relating to drug advertisements on social media or via telehealth.

The bill’s civil penalties apply when social media influencers or health care providers make communications regarding prescription drugs, using social media platforms, from which they financially benefit that (1) are made knowingly or recklessly and are false or inaccurate, or (2) fail to include the brief summary information (i.e., side effects, contraindications, effectiveness) required in drug advertisements. The Food and Drug Administration (FDA) must issue guidance and publish notice of such enforcement actions. The FDA may notify drug manufacturers when such communications fail to include the brief summary information.

The bill also requires telehealth providers (i.e., entities that use telecommunications to bring together patients and drug prescribers or dispensers) to include the brief summary information in prescription drug advertisements.

Also, payments from drug manufacturers to health care providers or social media influencers, or from health care providers to influencers, for communications promoting prescription drugs must be reported in accordance with anti-kickback laws for federal health care programs.

Additionally, the FDA may conduct market surveillance regarding prescription drug promotion on social media, including analyzing communications and establishing a task force with the Federal Trade Commission.

Show official title

A bill to provide for the regulation of certain communications regarding prescription drugs.

Referred to committee

Latest actionReferred to committee

This bill’s path

This is S. 652’s recorded path, not a universal congressional workflow.

How bills become lawAll actions
  1. Introduced

  2. Passed Senate

  3. Passed House

  4. Sent to President

  5. Signed into law

Sponsor
Sen. Richard J. Durbin (D-IL)
Cosponsors
1 cosponsor

1 original · 0 later

  1. Sen. Roger Marshall (R-KS)· Original · Feb 20, 2025
Policy area
Health
Subjects
  • Administrative law and regulatory procedures
  • Civil actions and liability
  • Congressional oversight
  • Department of Health and Human Services
  • Government information and archives
  • Health technology, devices, supplies
  • Internet, web applications, social media
  • Manufacturing
  • 2 more
    • Marketing and advertising
    • Prescription drugs

On this page

Timeline

i

In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.

  1. Introduced in Senate

    Document: Introduced in Senate

    Sources
  2. Latest

    Referred to committee

    Congressional Record S1129–S1130

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Sources

Committees

  1. SenateHealth, Education, Labor, and PensionsReferred Feb 20, 2025

Text & titles

i

Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.

Text versions
VersionDateLinks
Introduced in Senate
Titles (2)
  1. Protecting Patients from Deceptive Drug Ads Act

    Display title, Short title · Introduced in Senate

  2. A bill to provide for the regulation of certain communications regarding prescription drugs.

    Official title · Introduced in Senate